secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-048761
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M
-------------------------------------------------------------------

- Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
- Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.
- Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.
- New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.
- FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/0001193125-26-048761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-048761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer